Analysts predict that Stryker Co. (NYSE:SYK) will announce $3.51 billion in sales for the current quarter, Zacks reports. Eleven analysts have provided estimates for Stryker’s earnings. The highest sales estimate is $3.54 billion and the lowest is $3.46 billion. Stryker posted sales of $3.24 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 8.3%. The business is scheduled to announce its next quarterly earnings report on Thursday, April 25th.
According to Zacks, analysts expect that Stryker will report full-year sales of $14.80 billion for the current fiscal year, with estimates ranging from $14.57 billion to $14.88 billion. For the next fiscal year, analysts forecast that the firm will post sales of $15.78 billion, with estimates ranging from $15.52 billion to $15.93 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Stryker.
Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 29th. The medical technology company reported $2.18 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.15 by $0.03. Stryker had a return on equity of 27.60% and a net margin of 26.12%. The business had revenue of $3.80 billion during the quarter, compared to the consensus estimate of $3.73 billion.
Shares of Stryker stock traded up $0.69 on Friday, hitting $194.04. The stock had a trading volume of 1,734,335 shares, compared to its average volume of 1,481,983. Stryker has a 52-week low of $144.75 and a 52-week high of $194.80. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.41 and a current ratio of 2.02. The company has a market capitalization of $71.49 billion, a P/E ratio of 26.54, a PEG ratio of 2.34 and a beta of 0.88.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 1.07%. The ex-dividend date of this dividend is Thursday, March 28th. Stryker’s dividend payout ratio is presently 28.45%.
In other Stryker news, VP M Kathryn Fink sold 180 shares of the business’s stock in a transaction that occurred on Monday, February 4th. The stock was sold at an average price of $176.77, for a total transaction of $31,818.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Timothy J. Scannell sold 4,666 shares of the business’s stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $186.25, for a total value of $869,042.50. The disclosure for this sale can be found here. Insiders have sold a total of 74,811 shares of company stock worth $13,409,320 in the last quarter. 7.30% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in SYK. Oregon Public Employees Retirement Fund grew its holdings in shares of Stryker by 8,029.5% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,075,473 shares of the medical technology company’s stock worth $39,000 after acquiring an additional 6,000,739 shares during the period. Capital International Investors acquired a new stake in shares of Stryker in the 3rd quarter worth approximately $831,822,000. Norges Bank acquired a new stake in shares of Stryker in the 4th quarter worth approximately $474,132,000. Capital World Investors grew its holdings in shares of Stryker by 987.2% in the 3rd quarter. Capital World Investors now owns 1,657,979 shares of the medical technology company’s stock worth $294,590,000 after acquiring an additional 1,505,479 shares during the period. Finally, Winslow Capital Management LLC grew its holdings in shares of Stryker by 215,255.1% in the 3rd quarter. Winslow Capital Management LLC now owns 1,109,079 shares of the medical technology company’s stock worth $197,061,000 after acquiring an additional 1,108,564 shares during the period. Institutional investors and hedge funds own 75.46% of the company’s stock.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Featured Story: Is it better to buy a fund with a higher or lower NAV?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.